# Analysis of naïve Patients With Age-related Macular Degeneration Neovascular Type and Treated With Ranibizumab (Lucentis®) in Treat-and-extend at the CHU Brugmann.

> **NCT04988178** · — · COMPLETED · sponsor: **Brugmann University Hospital** · enrollment: 34 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **OTHER:** Data extraction from medical files

## Key facts

- **NCT ID:** NCT04988178
- **Lead sponsor:** Brugmann University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-13
- **Primary completion:** 2021-09-22
- **Final completion:** 2021-09-22
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04988178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04988178, "Analysis of naïve Patients With Age-related Macular Degeneration Neovascular Type and Treated With Ranibizumab (Lucentis®) in Treat-and-extend at the CHU Brugmann.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04988178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*